Viking Therapeutics Inc
Viking Therapeutics Inc (VKTX) Options Open Interest
VKTX options open interest is 353,111 contracts. The 2-week average daily volume is 24,561 contracts across the chain.
Read more
Monitoring VKTX open interest helps you see where real money is positioned on Viking Therapeutics Inc's options and which strikes are attracting the most commitment from traders. Viking Therapeutics Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor VKTX options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising VKTX options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Viking Therapeutics Inc to settle.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
The company was incorporated in 2012 and is headquartered in San Diego, California.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where VKTX open interest is concentrated. Our scanner maps Viking Therapeutics Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Viking Therapeutics Inc's options open interest as the signal it is, not as an afterthought.
| 50.00 | 0.05 | 0.12 | 0.09 | 132% | +0.0357 | 3,165 |
| 40.00 | 0.26 | 0.30 | 0.28 | 79% | +0.1492 | 1,776 |
| 35.00 | 1.55 | 1.74 | 1.65 | 70% | +0.5882 | 1,408 |
| 36.00 | 1.07 | 1.24 | 1.16 | 70% | +0.4703 | 1,296 |
| 45.00 | 0.05 | 0.19 | 0.12 | 105% | +0.0581 | 1,048 |
| 26.00 | — | 0.10 | 0.10 | 136% | -0.0360 | 1,227 |
| 25.00 | 0.03 | 0.05 | 0.04 | 128% | -0.0170 | 619 |
| 28.00 | — | 0.27 | 0.27 | 137% | -0.0830 | 386 |
| 23.00 | — | 0.58 | 0.58 | 269% | -0.0838 | 260 |
| 30.00 | — | 0.12 | 0.12 | 86% | -0.0636 | 258 |
As of September 25, 2026
Follow the money
Track VKTX open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→